Amid its recent decision to pump the brakes on the FDA application for its experimental Alzheimer’s drug donanemab, Eli Lilly appears to be casting a wider net in its efforts to improve treatment of the neurodegenerative disease.
Newly snared in that net is Quanterix, which is developing molecular diagnostic tools to detect and analyze disease biomarkers in the blood. Quanterix and Lilly are now joining forces with a primary goal of improving Alzheimer’s diagnoses using Quanterix’s technology and Lilly’s proprietary Alzheimer’s biomarker, plasma-based P-tau217.
Part of their agreement will give Quanterix nonexclusive global access to P-tau217, which it will be able to use first in the creation of new products and services for research use only and, eventually, to develop in vitro diagnostics for Alzheimer’s.
Related Posts
Industry Insights: Multi-omic Diagnostics
Multi-omic diagnostics are reshaping how researchers and clinicians approach complex diseases, offering deeper biological insights through the integration of multiple data types. In this interview with The Pathologist, industry experts…
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…